Department of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark.
Clin Endocrinol (Oxf). 2010 Jul;73(1):95-101. doi: 10.1111/j.1365-2265.2010.03791.x. Epub 2010 Jan 23.
Aneurysmal subarachnoid haemorrhage (SAH) has recently been reported as a common cause of chronic hypopituitarism, and introduction of routine neuroendocrine screening has been advocated. We aimed at estimating the risk of hypopituitarism after SAH using strict criteria including confirmatory testing in case of suggested insufficiency.
Cross-sectional evaluation with a nested prospective subgroup. Patients and measurements Endocrine evaluation was performed at a median of 14 months (range 11-26) post-SAH in 62 patients with SAH and 30 healthy controls. Twenty-six patients were followed prospectively (median 7 days, and 12 months post-SAH). Endocrine evaluation included baseline evaluation, which was combined with an insulin tolerance test (ITT) or, if contraindicated, GHRH + arginine tests and a standard ACTH test at evaluation 1-2 years post-SAH. Pituitary insufficiencies were confirmed by re-evaluation.
Early post-SAH hormone alterations mimicking central hypogonadism were present in 58% of the patients and associated with a worse clinical state (P < 0.05). One to 2 years post-SAH, initial neuroendocrine evaluation identified seven patients (11%) with abnormal results; three had free T4 and TSH suggestive of central hypothyroidism, three men had testosterone below 10 nm, and one had an insufficient GH and cortisol response to the ITT. None of these abnormalities was confirmed upon confirmatory testing.
In the largest reported cohort of patients with SAH to date, with early and late endocrine evaluation, none of the patients had chronic hypopituitarism. Based on these findings, the introduction of routine neuroendocrine screening is not justified, and the data suggest the importance of using strict diagnostic criteria in patients with a low pretest probability of hypopituitarism.
蛛网膜下腔出血(SAH)最近被报道为慢性垂体功能减退的常见原因,并且提倡常规进行神经内分泌筛查。我们旨在使用严格的标准,包括在提示功能不全的情况下进行确认性测试,来评估 SAH 后发生垂体功能减退的风险。
包括嵌套前瞻性亚组的横断面评估。
内分泌评估在 62 例 SAH 患者和 30 例健康对照者中的中位数为 14 个月(范围 11-26)后进行。26 例患者进行了前瞻性随访(中位数为 7 天和 SAH 后 12 个月)。内分泌评估包括基线评估,结合胰岛素耐量试验(ITT),或如果禁忌则进行 GHRH +精氨酸试验和标准 ACTH 试验,在 SAH 后 1-2 年进行评估。通过重新评估确认垂体功能减退。
SAH 后早期出现的激素改变模仿中枢性腺功能减退,在 58%的患者中存在,并与更差的临床状态相关(P<0.05)。1-2 年后的初始神经内分泌评估发现 7 例(11%)患者结果异常;3 例游离 T4 和 TSH 提示中枢性甲状腺功能减退,3 例男性睾酮低于 10nm,1 例 GH 和皮质醇对 ITT 的反应不足。在确认性测试中,这些异常均未得到证实。
在迄今为止报道的最大的 SAH 患者队列中,进行了早期和晚期内分泌评估,没有患者发生慢性垂体功能减退。基于这些发现,常规进行神经内分泌筛查是不合理的,并且数据表明在垂体功能减退的低术前可能性患者中使用严格的诊断标准的重要性。